November 3, 2026

QuidelOrtho Third Quarter 2026 Financial Results

QuidelOrtho™

© 2026 QuidelOrtho Corporation. All rights reserved.

Forward-Looking Statements and Non-GAAP Financial Measures

Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, including the expected results and anticipated benefits of the cost transformation and enterprise restructuring program and the timing and amount of related charges, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of today and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this presentation, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

Non-GAAP Financial Measures: This presentation contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to "constant currency revenue changes," "recurring revenue," "adjusted operating expenses," "adjusted operating expense changes," "adjusted EBITDA," "adjusted EBITDA margin," "adjusted gross profit margin," "adjusted gross profit margin changes," "adjusted diluted EPS," "adjusted diluted EPS changes," "adjusted tax rate," "free cash flow," "free cash flow changes" and other non-GAAP financial measures included in the reconciliation tables in the Appendix of this presentation. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results and comparison to competitors' operating results. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the Appendix or elsewhere within this presentation.

© 2026 QuidelOrtho Corporation. All rights reserved.

Basis of Presentation

- 2026 financials are as of the three and nine months ended September 27, 2026 and 2025 financials are as of the three and nine months ended September 28, 2025.
- Revenue growth rates are shown on a constant currency basis unless otherwise noted. The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period.
- Recurring revenue, a non-GAAP measure, means revenues from sales of our assays, reagents, consumables and services, and excludes instruments.
- Adjusted diluted earnings per share ("EPS") is a non-GAAP measure, which is calculated based on weighted-average shares outstanding. Diluted shares for 2026 were 69.1 million for the three months ended September 27, 2026 and 68.7 million for the nine months ended September 27, 2026. Diluted shares for 2025 were 68.1 million for the three months ended September 28, 2025 and 68.0 million for the nine months ended September 28, 2025.
- For full-year 2026 financial guidance, a reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors.
- Operating expenses is comprised of Selling, marketing and administrative and Research and development expenses.
- Free cash flow for the three months ended September 27, 2026 of $0.3 million represents $20 million of net cash provided by operating activities less $20 million of payments for acquisitions of property, plant, equipment, investments and intangibles ("capital expenditures") plus $1 million in proceeds from sale of property, plant and equipment ("capital disposals"). Free cash flow for the nine months ended September 27, 2026 of $(203) million represents $124 million of net cash used for operating activities less $81 million of payments for capital expenditures plus $2 million in proceeds from capital disposals.
- Net debt to adjusted EBITDA is based on management estimates for adjusted EBITDA (trailing twelve months) and net debt as of September 27, 2026.
- Pro forma debt leverage ratio includes pro forma EBITDA adjustments as of September 27, 2026, as defined and permitted under the terms of our credit agreement.

© 2026 QuidelOrtho Corporation. All rights reserved.

Q3 2026 Revenue Highlights



Across Key Healthcare Settings



Across Regions



Highly Recurring Revenue







See Non-GAAP Financial Measures on slide 2, Basis of Presentation on slide 3, and Appendix for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

YTD 2026 Revenue Highlights



Across Key Healthcare Settings



Across Regions



Highly Recurring Revenue







See Non-GAAP Financial Measures on slide 2, Basis of Presentation on slide 3, and Appendix for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

Q3 2026 Financial Results

Adj Operating Expenses

$210M

(3)% y/y

SM&A
$170M | (3)% y/y

R&D
$40M | (2)% y/y

Adj EBITDA

$148M

Adj. EBITDA Margin
23.9%

Adj Gross Profit Margin
47.8% | (90) bps y/y

Adj Diluted EPS

$0.31

(61)% y/y

Adj Tax Rate
27.4%

Depreciation
$69M

Cash

$166M

Free Cash Flow
$0.3M

Total Net Debt
$2.8B

Net Debt to Adj EBITDA
5.2x

Pro Forma Debt Leverage Under Credit Agreement
4.5x

See Non-GAAP Financial Measures on slide 2, Basis of Presentation on slide 3, and Appendix for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

YTD 2026 Financial Results

Adj Operating Expenses

$656M

(1)% y/y

SM&A
$529M | 1% y/y

R&D
$128M | (8)% y/y

Adj EBITDA

$386M

Adj. EBITDA Margin
20.6%

Adj Gross Profit Margin
45.3% | (300) bps y/y

Adj Diluted EPS

$0.41

(75)% y/y

Adj Tax Rate
26.7%

Depreciation
$203M

Free Cash Flow

$(203)M

(20)% y/y

Operating Cash Flow
$(124)M

Capital Expenditures
$81M

Capital Disposals
$2M

See Non-GAAP Financial Measures on slide 2, Basis of Presentation on slide 3, and Appendix for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

FY 2026 Financial Guidance

Financial Guidance	Updated (As of 11/3/2026)	Previous (As of 8/6/2026)
Total Revenues (Reported)	$2.52 - $2.54B	$2.52 - $2.60B
Adjusted EBITDA	$540 - $545M	$540 - $560M
Adjusted EBITDA Margin	~21%	21% - 22%
Adjusted Diluted EPS	$0.65 - $0.70	$0.65 - $0.90

Key Assumptions

- Revised financial guidance as of 11/3/2026 reflects a narrowing of the range due to continued demand headwinds in China related to the final IVD pricing guidelines
- Labs and Immunohematology revenue expected to continue to grow at low to mid-single digits, excluding China
- Depreciation is assumed to be $255 - $260 million
- Interest expense is assumed to be $219 - $223 million
- The effective tax rate is assumed to be ~27%
- Capital expenditure is assumed to be in the range of $115 - $125 million, excluding instruments under reagent rental agreements

See Forward-Looking Statements and Non-GAAP Financial Measures on slide 2 and Basis of Presentation on slide 3 for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

Appendix

QuidelOrtho™

Non-GAAP Adjustments

	Fiscal Quarter		Year to Date	
In millions	Q3 2026	Q3 2025	Q3 2026	Q3 2025
Employee compensation charges	$ 1.4	$ —	$ 5.8	$ —
Accelerated depreciation	2.0	1.5	6.1	2.5
Incremental depreciation on PP&E fair value adjustment	1.8	3.2	5.3	9.8
Amortization of deferred cloud computing implementation costs	0.7	0.7	2.1	2.1
Other adjustments	0.5	—	1.5	0.2
Cost of sales, excluding amortization of intangibles	**6.4**	**5.4**	**20.8**	**14.6**
Amortization of deferred cloud computing implementation costs	8.4	7.2	24.2	16.9
Employee compensation charges	2.2	—	7.2	—
Incremental depreciation on PP&E fair value adjustment	0.8	1.5	2.4	4.8
Credit Agreement amendment fees	0.5	—	0.5	—
Other adjustments	0.8	2.6	8.7	4.4
Selling, marketing and administrative	**12.7**	**11.3**	**43.0**	**26.1**
Incremental depreciation on PP&E fair value adjustment	0.8	0.4	2.2	1.1
EU medical device regulation transition costs	0.2	0.2	1.6	0.5
Employee compensation charges	0.1	—	0.7	—
Other adjustments	1.5	—	4.1	—
Research and development	**2.6**	**0.6**	**8.6**	**1.6**
Amortization of intangibles	**50.8**	**47.7**	**146.6**	**143.6**
Restructuring, integration and other charges	**7.1**	**39.6**	**18.0**	**234.6**
Goodwill impairment charge	**—**	**700.7**	**—**	**700.7**
Asset impairment charge	**12.5**	**9.7**	**12.5**	**9.7**
Legal accrual	—	9.4	—	9.4
Other adjustments	—	—	—	—
Other operating expenses	**—**	**9.4**	**—**	**9.4**
Increase to Operating loss	**92.1**	**824.4**	**249.5**	**1,140.3**
Interest expense, net	**—**	**—**	**—**	**—**
Loss on extinguishment of debt	**—**	**5.1**	**—**	**5.1**
Loss (gain) on investments	—	0.6	9.0	(0.7)
Tax indemnification expense	—	—	3.3	—
Other expense, net	**—**	**0.6**	**12.3**	**(0.7)**
Increase to Loss before income taxes	**92.1**	**830.1**	**261.8**	**1,144.7**
Income tax impact of adjustments	**(17.1)**	**(42.4)**	**4.7**	**(30.8)**
Increase to Net loss	**$ 75.0**	**$ 787.7**	**$ 266.5**	**$ 1,113.9**

© 2026 QuidelOrtho Corporation. All rights reserved.

Q3 2026 Non-GAAP Reconciliation

In millions	Fiscal Quarter Q3 2026			Fiscal Quarter Q3 2025		
	GAAP	Adjustments (1)	Non-GAAP	GAAP	Adjustments (1)	Non-GAAP
Gross profit	$ 289.6	$ 6.4	$ 296.0	$ 335.6	$ 5.4	$ 341.0
Selling, marketing and administrative	182.7	(12.7)	170.0	186.9	(11.3)	175.6
Research and development	42.5	(2.6)	39.9	41.5	(0.6)	40.9
Amortization of intangibles	50.8	(50.8)	—	47.7	(47.7)	—
Restructuring, integration and other charges	7.1	(7.1)	—	39.6	(39.6)	—
Goodwill impairment charge	—	—	—	700.7	(700.7)	—
Asset impairment charge	12.5	(12.5)	—	9.7	(9.7)	—
Other operating expenses	1.5	—	1.5	14.3	(9.4)	4.9
Operating (loss) income	(7.5)	92.1	84.6	(704.8)	824.4	119.6
Operating margin	(1.2)%		13.7 %	(100.7)%		17.1 %
Interest expense, net	55.4	—	55.4	46.1	—	46.1
Loss on extinguishment of debt	—	—	—	5.1	(5.1)	—
Other expense, net	—	—	—	0.9	(0.6)	0.3
(Loss) income before income taxes	(62.9)	92.1	29.2	(756.9)	830.1	73.2
(Benefit from) provision for income taxes	(9.1)	17.1	8.0	(23.9)	42.4	18.5
Net (loss) income	**$ (53.8)**	**$ 75.0**	**$ 21.2**	**$ (733.0)**	**$ 787.7**	**$ 54.7**

(1) Refer to schedule on the Non-GAAP Adjustments slide for further details.

© 2026 QuidelOrtho Corporation. All rights reserved.

Q3 2026 YTD Non-GAAP Reconciliation

In millions	Year to Date Q3 2026			Year to Date Q3 2025		
	GAAP	Adjustments [1]	Non-GAAP	GAAP	Adjustments [1]	Non-GAAP
Gross profit	$ 826.3	$ 20.8	$ 847.1	$ 953.8	$ 14.6	$ 968.4
Selling, marketing and administrative	571.7	(43.0)	528.7	551.9	(26.1)	525.8
Research and development	136.1	(8.6)	127.5	140.4	(1.6)	138.8
Amortization of intangibles	146.6	(146.6)	—	143.6	(143.6)	—
Restructuring, integration and other charges	18.0	(18.0)	—	234.6	(234.6)	—
Goodwill impairment charge	—	—	—	700.7	(700.7)	—
Asset impairment charge	12.5	(12.5)	—	9.7	(9.7)	—
Other operating expenses	2.5	—	2.5	25.8	(9.4)	16.4
Operating (loss) income	(61.1)	249.5	188.4	(852.9)	1,140.3	287.4
Operating margin	(3.3)%		10.1 %	(42.5)%		14.3 %
Interest expense, net	161.2	—	161.2	126.6	—	126.6
Loss on extinguishment of debt	—	—	—	5.1	(5.1)	—
Other expense, net	1.3	(12.3)	(11.0)	10.7	0.7	11.4
(Loss) income before income taxes	(223.6)	261.8	38.2	(995.3)	1,144.7	149.4
Provision for income taxes	14.9	(4.7)	10.2	5.8	30.8	36.6
Net (loss) income	**$ (238.5)**	**$ 266.5**	**$ 28.0**	**$ (1,001.1)**	**$ 1,113.9**	**$ 112.8**

(1) Refer to schedule on the Non-GAAP Adjustments slide for further details.

© 2026 QuidelOrtho Corporation. All rights reserved.

Revenue by Geography

Three Months Ended

$ in millions	2025				2026			Third Quarter		
	Q1	Q2	**Q3**	Q4	Q1	Q2	**Q3**	**Percent Change**	**Currency Impact**	**Constant Currency [1]**
North America	$406.7	$310.7	$381.4	$390.1	$328.9	$327.4	$330.7	(13.3)%	0.1%	(13.4)%
EMEA	88.9	87.3	91.8	92.7	92.5	91.2	86.9	(5.3)%	(2.5)%	(2.8)%
China	75.0	83.4	84.6	91.7	63.5	67.8	48.9	(42.2)%	3.3%	(45.5)%
JPAC	68.1	72.2	76.8	75.9	70.0	74.3	76.4	(0.5)%	(8.0)%	7.5%
Latin America	54.1	60.3	65.3	73.2	64.9	70.2	76.0	16.4%	6.9%	9.5%
Total Revenue	$692.8	$613.9	**$699.9**	$723.6	$619.8	$630.9	**$618.9**	**(11.6)%**	**—%**	**(11.6)%**

Year to Date

$ in millions	2025			2026		Nine Months		
	6 Months	**9 Months**	Year	6 Months	**9 Months**	**Percent Change**	**Currency Impact**	**Constant Currency [1]**
North America	$717.4	$1,098.8	$1,488.9	$656.3	$987.0	(10.2)%	(0.2)%	(10.0)%
EMEA	176.2	268.0	360.7	183.7	270.6	1.0%	3.5%	(2.5)%
China	158.4	243.0	334.7	131.3	180.2	(25.8)%	3.8%	(29.6)%
JPAC	140.3	217.1	293.0	144.3	220.7	1.7%	(5.9)%	7.6%
Latin America	114.4	179.7	252.9	135.1	211.1	17.5%	8.6%	8.9%
Total Revenue	$1,306.7	**$2,006.6**	$2,730.2	$1,250.7	**$1,869.6**	**(6.8)%**	**1.0%**	**(7.8)%**

(1) See Basis of Presentation on slide 3 for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

Revenue by Business Unit

Three Months Ended

$ in millions	2025				2026			Third Quarter		
	Q1	Q2	**Q3**	Q4	Q1	Q2	**Q3**	**Percent Change**	**Currency Impact**	**Constant Currency (1)**
Labs	$373.0	$369.7	$373.8	$389.2	$353.1	$382.9	$353.2	(5.5)%	0.4%	(5.9)%
Immunohematology	128.5	132.3	142.0	141.0	138.3	134.2	142.0	—%	(0.9)%	0.9%
Donor Screening	12.8	13.3	14.7	11.8	7.8	4.0	1.7	(88.4)%	—%	(88.4)%
Point of Care	170.9	93.0	164.6	173.1	112.8	108.2	119.6	(27.3)%	(0.1)%	(27.2)%
Molecular Diagnostics	7.6	5.6	4.8	8.5	7.8	1.6	2.4	(50.0)%	(0.7)%	(49.3)%
Total Revenue	$692.8	$613.9	**$699.9**	$723.6	$619.8	$630.9	**$618.9**	**(11.6)%**	**—%**	**(11.6)%**

Year to Date

$ in millions	2025			2026		Nine Months		
	6 Months	**9 Months**	Year	6 Months	**9 Months**	**Percent Change**	**Currency Impact**	**Constant Currency (1)**
Labs	$742.7	$1,116.5	$1,505.7	$736.0	$1,089.2	(2.4)%	1.3%	(3.7)%
Immunohematology	260.8	402.8	543.8	272.5	414.5	2.9%	1.2%	1.7%
Donor Screening	26.1	40.8	52.6	11.8	13.5	(66.9)%	—%	(66.9)%
Point of Care	263.9	428.5	601.6	221.0	340.6	(20.5)%	0.4%	(20.9)%
Molecular Diagnostics	13.2	18.0	26.5	9.4	11.8	(34.4)%	1.2%	(35.6)%
Total Revenue	$1,306.7	**$2,006.6**	$2,730.2	$1,250.7	**$1,869.6**	**(6.8)%**	**1.0%**	**(7.8)%**

(1) See Basis of Presentation on slide 3 for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

Revenue by Respiratory and Non-Respiratory

Three Months Ended

$ in millions	2025				2026			Third Quarter		
	Q1	Q2	**Q3**	Q4	Q1	Q2	**Q3**	**Percent Change**	**Currency Impact**	**Constant Currency (1)**
Respiratory Revenue	$119.8	$46.7	$112.3	$123.3	$67.9	$47.9	$68.8	(38.7)%	—%	(38.7)%
Non-Respiratory Revenue	573.0	567.2	587.6	600.3	551.9	583.0	550.1	(6.4)%	—%	(6.4)%
Total Revenue	$692.8	$613.9	**$699.9**	$723.6	$619.8	$630.9	**$618.9**	**(11.6)%**	**—%**	**(11.6)%**

Year to Date

$ in millions	2025			2026		Nine Months		
	6 Months	**9 Months**	Year	6 Months	**9 Months**	**Percent Change**	**Currency Impact**	**Constant Currency (1)**
Respiratory Revenue	$166.5	$278.8	$402.1	$115.8	$184.6	(33.8)%	0.1%	(33.9)%
Non-Respiratory Revenue	1,140.2	1,727.8	2,328.1	1,134.9	1,685.0	(2.5)%	1.2%	(3.7)%
Total Revenue	$1,306.7	**$2,006.6**	$2,730.2	$1,250.7	**$1,869.6**	**(6.8)%**	**1.0%**	**(7.8)%**

(1) See Basis of Presentation on slide 3 for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

Non-GAAP Reconciliations

Three Months Ended					
$ in millions	September 27, 2026	September 28, 2025	Percent Change	Currency Impact	Constant Currency (1)
Total revenues	$618.9	$699.9	(11.6)%	—%	(11.6)%
Respiratory	68.8	112.3	(38.7)%	—%	(38.7)%
China excluding respiratory	48.4	84.4	(42.7)%	3.2%	(45.9)%
U.S. Donor Screening	0.5	13.1	(96.0)%	—%	(96.0)%
Total revenues excluding respiratory, China, and U.S. Donor Screening	**$501.2**	**$490.1**	**2.3%**	**(0.7)%**	**3.0%**

Three Months Ended					
$ in millions	September 27, 2026	September 28, 2025	Percent Change	Currency Impact	Constant Currency (1)
Labs	$353.2	$373.8	(5.5)%	0.4%	(5.9)%
China Labs	36.9	67.7	(45.5)%	3.2%	(48.7)%
Total Labs revenues excluding China	**$316.3**	**$306.1**	**3.3%**	**(0.5)%**	**3.8%**

Three Months Ended					
$ in millions	September 27, 2026	September 28, 2025	Percent Change	Currency Impact	Constant Currency (1)
Immunohematology	$142.0	$142.0	—%	(0.9)%	0.9%
China Immunohematology	8.0	10.2	(21.6)%	4.1%	(25.7)%
Total Immunohematology revenues excluding China	**$134.0**	**$131.8**	**1.7%**	**(1.3)%**	**3.0%**

(1) See Basis of Presentation on slide 3 for additional information.

© 2026 QuidelOrtho Corporation. All rights reserved.

Non-GAAP Reconciliations – Adjusted EBITDA

	Fiscal Quarter		Year to Date	
In millions	Q3 2026	Q3 2025	Q3 2026	Q3 2025
Net loss	**$ (53.8)**	**$ (733.0)**	**$ (238.5)**	**$ (1,001.1)**
Depreciation and amortization	119.6	112.1	349.2	329.5
Interest expense, net	55.4	46.1	161.2	126.6
(Benefit from) provision for income taxes	(9.1)	(23.9)	14.9	5.8
Restructuring, integration and other charges	7.1	39.6	18.0	234.6
Goodwill impairment charge	—	700.7	—	700.7
Asset impairment charge	12.5	9.7	12.5	9.7
Loss on extinguishment of debt	—	5.1	—	5.1
Legal accrual	—	9.4	—	9.4
Amortization of deferred cloud computing implementation costs	9.1	7.9	26.3	19.0
Employee compensation charges	3.7	—	13.7	—
Tax indemnification expense	—	—	3.3	—
EU medical device regulation transition costs	0.2	0.2	1.6	0.5
Loss (gain) on investments	—	0.6	9.0	(0.7)
Credit Agreement amendment fees	0.5	—	0.5	—
Other adjustments	2.8	2.6	14.3	4.6
Adjusted EBITDA	**$ 148.0**	**$ 177.1**	**$ 386.0**	**$ 443.7**

© 2026 QuidelOrtho Corporation. All rights reserved.

QuidelOrtho™

quidelortho.com